- Oxford study finds increased risks of dementia two years after contracting COVID-19
- 14 hospitals in Japan issued a “blood warning”
- Inconspicuous vitamin K can effectively inhibit cell ferroptosis
- What is the practical significance when WHO declares monkeypox as a public health event of international concern?
- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
Good News: COVID-19 vaccines for children under 12 will be available soon
- Israel new drug for COVID-19: EXO-CD24 can reduce deaths by 50%
- COVID-19 vaccines for children under 12 will be available soon
- Breakthrough infection of Delta: No difference from regular COVID-19 cases
- French research: ADE occurred in Delta variant and many doubts on it
- The viral load of Delta variant is 1260 times the original COVID-19 strain
COVID-19 vaccines for children under 12 will be available soon. Vaccines for adults are being widely promoted around the world, but as of now, there is still no vaccine suitable for children under 12 years old, which makes the majority of parents feel anxious.
Both Pfizer and Moderna have involved young children in clinical trials in March, but the results of these studies have not yet been announced. Pfizer has news that it is expected to obtain data on the effectiveness of its vaccine in children aged 5 to 11 by the end of September.
After that, the FDA usually takes a few weeks to review the authenticity and safety of these data. Therefore, if the test results are good, then a vaccine suitable for children under 12 years old can be marketed as early as October this year. At the same time, Moderna expects to seek emergency authorization for children under 12 in the winter or early next year, when the children will be much safer.
Pfizer’s first phase trial showed that a lower dose of the vaccine (10 micrograms instead of 30 micrograms for adults) is safe in children between 5 and 11 years of age. The trial used a smaller dose for younger children, namely 3 micrograms for children 6 months to 5 years old.
The situation with Moderna is similar. Their standard dosing regimen is 100 micrograms. In the trial, children from 2 to 12 years old received 50 or 100 micrograms, and children 6 months to 2 years old received 25, 50, or 100 micrograms.
Lower doses can help avoid unnecessary side effects: Adolescents in the Pfizer trial appear to have side effects more frequently than adults, which may be due to the rapid recovery of the child’s immune system. But even the most common side effects, such as fatigue and headaches, are relatively minor.
According to data from a Phase 3 trial conducted by Pfizer in adults, the trial included more than 2,000 participants between the ages of 12 and 15 and the results showed that the safety of the vaccine in adolescents is similar to that of the elderly.
(source:internet, reference only)